This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-small Cell Lung Cancer (JCOG0403)

This study has been completed.
Sponsor:
Collaborator:
Ministry of Health, Labour and Welfare, Japan
Information provided by (Responsible Party):
Haruhiko Fukuda, Japan Clinical Oncology Group
ClinicalTrials.gov Identifier:
NCT00238875
First received: October 13, 2005
Last updated: September 21, 2016
Last verified: September 2016
  Purpose
To evaluate the efficacy and safety of SBRT for T1N0M0 non-small cell lung cancer

Condition Intervention Phase
T1N0M0 Non-small Cell Lung Cancer Procedure: stereotactic body radiation therapy Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-small Cell Lung Cancer (JCOG0403)

Resource links provided by NLM:


Further study details as provided by Haruhiko Fukuda, Japan Clinical Oncology Group:

Primary Outcome Measures:
  • 3-years overall survival [ Time Frame: During the study conduct ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: During the study conduct ]
  • relapse-free survival [ Time Frame: During the study conduct ]
  • local-relapse free survival [ Time Frame: During the study conduct ]
  • 3-years local relapse free survival [ Time Frame: During the study conduct ]
  • patterns of relapse [ Time Frame: During the study conduct ]
  • acute complications [ Time Frame: within 8 weeks from starting treatment day ]
  • late complications [ Time Frame: after 8 weeks from starting treatment day ]
  • serious complication rate [ Time Frame: During the study conduct ]

Enrollment: 167
Study Start Date: July 2004
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Procedure/Surgery: stereotactic body radiation therapy
Procedure: stereotactic body radiation therapy
Procedure/Surgery: stereotactic body radiation therapy

Detailed Description:
To evaluate the efficacy and safety of SBRT for T1N0M0 non-small cell lung cancer,the following questions should be answered. Can SRT be an alternative standard treatment modality for inoperable patients? Can SRT can be a comparable standard treatment modality with lobectomy for operable patients? 12 Gy is the daily dose at the isocenter,and 48 Gy in total by 4 fractions will be irradiated by stereotactic irradiation over 4 to 8 days.
  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or transbronchoscopic cytologically confirmed non-small cell lung cancer
  2. Stage IA with images within 28 days
  3. No other intrathoracic lesions
  4. Dose constraints of the organs at risk seem to be limited within range
  5. Operable (Standard or Limited surgery) or Inoperable
  6. Age>=20
  7. No previous thoracic radiation
  8. No previous chemotherapy
  9. ECOG PS=0-2
  10. Respiratory function (<=14 days) PaO2>=60 torr FEV1.0>=700 ml
  11. Written informed consent

Exclusion Criteria:

  1. No apparent radiation pneumonitis and fibrosis
  2. No active tuberculosis without oral drugs
  3. No double cancer
  4. No pregnancy
  5. No psychiatric disorder
  6. No steroid administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00238875

Locations
Japan
Kyushu University Hospital
Fukuoka,Higashi-ku,Maidashi,3-1-1, Fukuoka, Japan, 812-8582
Hiroshima University, School of Medicine
Hiroshima,Minami-ku,Kasumi,1-2-3, Hiroshima, Japan, 734-8551
Hokkaido University Hospital
North-14 West-5 Kita-ku,Sapporo, Hokkaido, Japan, 060-8648
Sapporo Medical University
S-1,W-16,Chuo-ku,Sapporo, Hokkaido, Japan, 060-8543
Institute of Biomedical Research and Innovation Hospital
Kobe,Chuo-ku,Minatojima-Minamimachi,2-2, Hyogo, Japan, 650-0047
Kitasato University School of Medicine
Sagamihara,Kitasato,1-15-1, Kanagawa, Japan, 228-8555
Kyoto Universlty Hospital
Kyoto,Sakyoku,Shogoin,Kawahara-cho,54, Kyoto, Japan, 606-8507
Tohoku University Hospital
Sendai,Aoba-ku,Seiryo-machi,1-1, Miyagi, Japan, 980-8574
Tenri Hospital
Tenri,Mishima-cho,200, Nara, Japan, 632-8552
The University of Tokyo Hospital
Bunkyo-ku,Hongo,7-3-1, Tokyo, Japan, 113-8655
Tokyo Metropolitan Komagome Hospital
Bunkyo-ku,Honkomagome,3-18-22, Tokyo, Japan, 113-8677
Nihon University Itabashi Hospital
Itabashi-ku,Oyaguchikamimachi,30-1, Tokyo, Japan, 173-8610
Cancer Institute Hospital
Koto-ku,Ariake,3-10-6, Tokyo, Japan, 135-8550
Tokyo Women's Medical University
Shinjuku-ku,Kawada-cho,8-1, Tokyo, Japan, 162-8666
Keio University Hospital
Shinjuku-ku,Shinanomachi,35, Tokyo, Japan, 160-8582
University of Yamanashi Faculty of Medicine
Nakakoma,Tamaho,Shimokato,1110, Yamanashi, Japan, 409-3898
Sponsors and Collaborators
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan
Investigators
Study Chair: Masahiro Hiraoka, MD, PhD Kyoto Universlty Hospital
  More Information

Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Haruhiko Fukuda, JCOG Data Center, Japan Clinical Oncology Group
ClinicalTrials.gov Identifier: NCT00238875     History of Changes
Other Study ID Numbers: JCOG0403
C000000029
Study First Received: October 13, 2005
Last Updated: September 21, 2016

Keywords provided by Haruhiko Fukuda, Japan Clinical Oncology Group:
stereotactic body radiation therapy
T1N0M0 non-small cell lung cancer
radiotherapy

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms

ClinicalTrials.gov processed this record on September 21, 2017